VEGFA and neoplasm: Based on the preclinical pharmacodynamics and toxicological study data for ivonescimab [15] and the promising evidence of clinical efficacy with manageable safety profile that have been observed for the combination of anti‐PD‐1/L1 and anti‐VEGF drugs across a range of tumor types in early or late‐stage clinical trials, we have sound scientific rationales for clinical investigation of ivonescimab in patients with solid tumors.